Literature DB >> 17926052

MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy.

Kalman Kovacs, Bernd W Scheithauer, Matilde Lombardero, Roger E McLendon, Luis V Syro, Humberto Uribe, Leon D Ortiz, Luis C Penagos.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17926052     DOI： 10.1007/s00401-007-0279-5

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN： 0001-6322            Impact factor:   17.088


× No keyword cloud information.
  34 in total

Review 1.  Temozolomide responsiveness in aggressive corticotroph tumours: a case report and review of the literature.

Authors:  A K Annamalai; A F Dean; N Kandasamy; K Kovacs; H Burton; D J Halsall; A S Shaw; N M Antoun; H K Cheow; R W Kirollos; J D Pickard; H L Simpson; S J Jefferies; N G Burnet; M Gurnell
Journal:  Pituitary       Date:  2012-09       Impact factor: 4.107

Review 2.  Clinical review: Pituitary carcinoma: difficult diagnosis and treatment.

Authors:  Anthony P Heaney
Journal:  J Clin Endocrinol Metab       Date:  2011-09-28       Impact factor: 5.958

3.  Mid-term prognosis of non-functioning pituitary adenomas with high proliferative potential: really an aggressive variant?

Authors:  Yoshikazu Ogawa; Hidefumi Jokura; Kuniyasu Niizuma; Teiji Tominaga
Journal:  J Neurooncol       Date:  2018-01-09       Impact factor: 4.130

4.  Temozolomide for corticotroph pituitary adenomas refractory to standard therapy.

Authors:  Troy H Dillard; S Humayun Gultekin; Johnny B Delashaw; Chris G Yedinak; Edward A Neuwelt; Maria Fleseriu
Journal:  Pituitary       Date:  2011-03       Impact factor: 4.107

Review 5.  Molecular basis of pharmacological therapy in Cushing's disease.

Authors:  Diego Ferone; Claudia Pivonello; Giovanni Vitale; Maria Chiara Zatelli; Annamaria Colao; Rosario Pivonello
Journal:  Endocrine       Date:  2013-11-23       Impact factor: 3.633

6.  MGMT immunoexpression in silent subtype 3 pituitary adenomas: possible therapeutic implications.

Authors:  Michael E Fealey; Bernd W Scheithauer; Eva Horvath; Dana Erickson; Kalman Kovacs; Roger McLendon; Ricardo V Lloyd
Journal:  Endocr Pathol       Date:  2010-09       Impact factor: 3.943

Review 7.  Management of aggressive pituitary adenomas and pituitary carcinomas.

Authors:  Anthony Heaney
Journal:  J Neurooncol       Date:  2014-03-02       Impact factor: 4.130

8.  Invasive adenoma and pituitary carcinoma: a SEER database analysis.

Authors:  Tara M Hansen; Sachin Batra; Michael Lim; Gary L Gallia; Peter C Burger; Roberto Salvatori; Gary Wand; Alfredo Quinones-Hinojosa; Lawrence Kleinberg; Kristin J Redmond
Journal:  Neurosurg Rev       Date:  2014-02-14       Impact factor: 3.042

9.  Temozolomide (Temodar®) and capecitabine (Xeloda®) treatment of an aggressive corticotroph pituitary tumor.

Authors:  Marie S Thearle; Pamela U Freda; Jeffrey N Bruce; Steven R Isaacson; Yoomi Lee; Robert L Fine
Journal:  Pituitary       Date:  2011-12       Impact factor: 4.107

10.  Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas.

Authors:  Marco Losa; Fausto Bogazzi; Salvo Cannavo; Filippo Ceccato; Lorenzo Curtò; Laura De Marinis; Donato Iacovazzo; Giuseppe Lombardi; Giovanna Mantovani; Elena Mazza; Giuseppe Minniti; Maurizio Nizzoli; Michele Reni; Carla Scaroni
Journal:  J Neurooncol       Date:  2015-11-27       Impact factor: 4.130
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.